Table 6. Poole results for the associations between MGMT promoter hypermethylation and clincopathological features of CC.
| Clincopathological features | Studies (N) | Patients (N) | Heterogeneity | Modela | Effect size | ||
|---|---|---|---|---|---|---|---|
| I2(%) | PQ-test | OR (95% CI) | P | ||||
| Histological types (SCC vs. AdC) | 8 | 475 | 0 | 0.73 | F | 0.73(0.43–1.26) | 0.26 |
| FIGO stage (I+II vs. III+IV) | 9 | 560 | 0 | 0.43 | F | 2.81(1.79–4.41) | <0.001 |
| Histological grade(G3 vs. G1+G2) | 7 | 433 | 54 | 0.04 | R | 1.15(0.49–2.68) | 0.74 |
| HPV infection(Positive vs. Negative) | 2 | 850 | 96 | <0.001 | R | 17.24(0.02–190.55) | 0.43 |
| Therapeutic response (Yes vs. No) | 2 | 206 | 0 | 0.85 | F | 1.65(0.80–3.38) | 0.17 |
| Age at diagnoses (<50 vs. ≥50) | 2 | 720 | 0 | 0.98 | F | 1.40(0.93–2.10) | 0.11 |
| Lymph node metastasis (Yes vs. No) | 2 | 66 | 1 | 0.32 | R | 4.91(1.56–15.42) | 0.007 |
Abbreviations: N, number; SCC, squamous cell carcinoma; AdC, adenocinoma; F, fixed-effects model; R, random-effects model.
Notes
aWhen significant heterogeneity was found (I2≥50% or PQ-test≤0.1), a random-effects model with the inverse variance method was used to pool the results; otherwise, a fixed-effects model was applied.